Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia.
Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.
Study Overview
Status
Conditions
Detailed Description
Investigators will achieved the following data from the participants:
- Demographic
- Past medical/habitual history
- COVID-19 status and related risk factors
- Mucormycosis status and related risk factors
- Ocular examination and imaging
- Follow-up
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Mohsen Pourazizi, M.D.
- Phone Number: 00983134452036
- Email: m.pourazizi@med.mui.ac.ir
Study Locations
-
-
-
Isfahan, Iran, Islamic Republic of, +98
- Recruiting
- Isfahan University of Medical Sciences
-
Contact:
- Mohsen Pourazizi
- Phone Number: +98
- Email: m.pourazizi@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosed case of Mucormycosis in COVID-19 pandemic
Exclusion Criteria:
- People with acute or severely ill conditions that prevent them from ophthalmic examination.
- Patient, or legal representative opposing the pursuit of the research
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vision loss
Time Frame: 3 months
|
Prevalence of Vision loss in COVID-19 patients with Mucormycosis co-infection
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Risk factors
Time Frame: 3 months
|
Related risk factors for vision loss
|
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mohsen Pourazizi, M.D., Isfahan Eye Research Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IR.MUI.MED.REC.1400.572
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.